Rodriguez-Rodriguez L - Search Results

1

Rab1 in cell signaling, cancer and other diseases.

Yang XZ, Li XX, Zhang YJ, Rodriguez-Rodriguez L, Xiang MQ, Wang HY, Zheng XF. Yang XZ, et al. Oncogene. 2016 Nov 3;35(44):5699-5704. doi: 10.1038/onc.2016.81. Epub 2016 Apr 4. Oncogene. 2016. PMID: 27041585 Free PMC article. Review.

2

Tumor necrosis factor-alpha differentially modulates CD44 expression in ovarian cancer cells.

Muthukumaran N, Miletti-González KE, Ravindranath AK, Rodríguez-Rodríguez L. Muthukumaran N, et al. Mol Cancer Res. 2006 Aug;4(8):511-20. doi: 10.1158/1541-7786.MCR-05-0232. Mol Cancer Res. 2006. PMID: 16908592

3

RET rearrangements are actionable alterations in breast cancer.

Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, Schrock AB, Gay LM, Lee E, Dolfi SC, Pham K, Lin S, Yao M, Kulkarni A, DiClemente F, Liu C, Rodriguez-Rodriguez L, Ganesan S, Ross JS, Ali SM, Leyland-Jones B, Hirshfield KM. Paratala BS, et al. Nat Commun. 2018 Nov 16;9(1):4821. doi: 10.1038/s41467-018-07341-4. Nat Commun. 2018. PMID: 30446652 Free PMC article.

4

The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer.

Miletti-González KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, Apolito K, Shih WJ, Hait WN, Rodríguez-Rodríguez L. Miletti-González KE, et al. Cancer Res. 2005 Aug 1;65(15):6660-7. doi: 10.1158/0008-5472.CAN-04-3478. Cancer Res. 2005. PMID: 16061646

5

Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Shah V, et al. Clin Cancer Res. 2013 Nov 15;19(22):6193-204. doi: 10.1158/1078-0432.CCR-13-1536. Epub 2013 Sep 13. Clin Cancer Res. 2013. PMID: 24036854 Free PMC article.

6

HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.

Khella CA, Franciosa L, Rodirguez-Rodriguez L, Rajkarnikar R, Mythreye K, Gatza ML. Khella CA, et al. Mol Cancer Res. 2023 Oct 2;21(10):1037-1049. doi: 10.1158/1541-7786.MCR-22-0496. Mol Cancer Res. 2023. PMID: 37342066

7

Impact of body mass index on ovarian cancer survival varies by stage.

Bandera EV, Lee VS, Qin B, Rodriguez-Rodriguez L, Powell CB, Kushi LH. Bandera EV, et al. Br J Cancer. 2017 Jul 11;117(2):282-289. doi: 10.1038/bjc.2017.162. Epub 2017 Jun 6. Br J Cancer. 2017. PMID: 28588323 Free PMC article.

8

Nutritional factors in ovarian cancer survival.

Bandera EV, Kushi LH, Rodriguez-Rodriguez L. Bandera EV, et al. Nutr Cancer. 2009;61(5):580-6. doi: 10.1080/01635580902825670. Nutr Cancer. 2009. PMID: 19838931 Review.

9

Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element.

Miletti-González KE, Murphy K, Kumaran MN, Ravindranath AK, Wernyj RP, Kaur S, Miles GD, Lim E, Chan R, Chekmareva M, Heller DS, Foran D, Chen W, Reiss M, Bandera EV, Scotto K, Rodríguez-Rodríguez L. Miletti-González KE, et al. J Biol Chem. 2012 Jun 1;287(23):18995-9007. doi: 10.1074/jbc.M111.318774. Epub 2012 Mar 20. J Biol Chem. 2012. PMID: 22433859 Free PMC article. Clinical Trial.

10

Total and individual antioxidant intake and risk of epithelial ovarian cancer.

Gifkins D, Olson SH, Paddock L, King M, Demissie K, Lu SE, Kong AN, Rodriguez-Rodriguez L, Bandera EV. Gifkins D, et al. BMC Cancer. 2012 Jun 1;12:211. doi: 10.1186/1471-2407-12-211. BMC Cancer. 2012. PMID: 22656322 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page